# A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

> **NCT05216237** · PHASE2 · UNKNOWN · sponsor: **Jiuda Zhao** · enrollment: 31 (estimated)

## Conditions studied

- Gastric Cancer
- Chemotherapy
- Immunotherapy

## Interventions

- **DRUG:** Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)

## Key facts

- **NCT ID:** NCT05216237
- **Lead sponsor:** Jiuda Zhao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-15
- **Primary completion:** 2024-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2022-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05216237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05216237, "A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05216237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*